MedTrace Logo

The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)

NCT01354093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2017-06-23

No results posted yet for this study

Summary

Macular telangiectasia type 2 ("MacTel Type 2") is an uncommon eye disorder that results in slow vision loss beginning in middle age. The macula is the central part of the retina, which lines the back of the eye like the film of a camera. The macula is responsible for central or reading vision. Telangiectasis refers to dilated, leaky vessels, for example varicose veins in the legs. One of the earliest manifestations of macular telangiectasia type 2 is an acquired reduction and/or redistribution of the macular pigment carotenoids at the foveal center. Currently, the biochemical mechanisms and clinical significance underlying these changes are not known, but it seems likely that better understanding of this phenomenon could lead to new interventions against MacTel.

The objectives of this study are to image the maculas of MacTel subjects using two-wavelength autofluorescence imaging and resonance Raman imaging to target the 7-degree radius pigment ring characteristic of macular telangiectasia type 2 in order to gain further insight into the significance of this early clinical sign, and to evaluate whether supplementation with oral zeaxanthin can normalize macular pigment distribution in MacTel subjects

Conditions

  • Idiopathic Juxtafoveal Telangiectasia

Interventions

DRUG

zeaxanthin

10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day

DRUG

zeaxanthin

10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day

Sponsors & Collaborators

  • Paul S. Bernstein

    lead OTHER

Principal Investigators

  • Paul S. Bernstein, M.D., Ph.D. · University of Utah

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354093 on ClinicalTrials.gov